Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-05-14

FDA Approved: OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE — Original Application (Slate Run Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved Slate Run Pharmaceuticals' generic fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide under an origin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide (olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide)

Snippet

ORIG AP for OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE)